AstraZeneca is set to release its Q3 results with expected core EPS of $2.04 and sales of $13.1 billion. Market focus on FDA approval for lung cancer drug and regulatory issues in China impacting share prices.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
